André Jefremow

565 total citations
12 papers, 329 citations indexed

About

André Jefremow is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, André Jefremow has authored 12 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Genetics and 3 papers in Molecular Biology. Recurrent topics in André Jefremow's work include Inflammatory Bowel Disease (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers) and Colorectal Cancer Surgical Treatments (2 papers). André Jefremow is often cited by papers focused on Inflammatory Bowel Disease (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers) and Colorectal Cancer Surgical Treatments (2 papers). André Jefremow collaborates with scholars based in Germany and United States. André Jefremow's co-authors include Markus F. Neurath, Maximilian J. Waldner, Clemens Neufert, Christoph Becker, Raja Atreya, Michael Vieth, Benno Weigmann, Stefan Rose‐John, Stefan Wirtz and Patricia Klinger and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

André Jefremow

12 papers receiving 321 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
André Jefremow Germany 7 122 117 87 73 60 12 329
Zhehui Zhu China 8 86 0.7× 165 1.4× 34 0.4× 59 0.8× 54 0.9× 18 332
Guo‐Qing Tao China 10 167 1.4× 164 1.4× 31 0.4× 40 0.5× 62 1.0× 19 333
Judit López‐Luque Spain 8 95 0.8× 179 1.5× 80 0.9× 41 0.6× 70 1.2× 8 368
Yoshikazu Kuboi Japan 12 100 0.8× 84 0.7× 125 1.4× 34 0.5× 17 0.3× 23 325
Hugues de Boussac France 13 107 0.9× 214 1.8× 35 0.4× 96 1.3× 94 1.6× 27 382
Souhir Mestiri Tunisia 9 124 1.0× 163 1.4× 131 1.5× 70 1.0× 112 1.9× 17 390
Benjamin L. Emmink Netherlands 10 131 1.1× 281 2.4× 86 1.0× 37 0.5× 114 1.9× 23 496
N. Gavalas Greece 7 92 0.8× 166 1.4× 120 1.4× 49 0.7× 46 0.8× 9 337
Domenico Zito Italy 8 117 1.0× 164 1.4× 78 0.9× 111 1.5× 123 2.0× 12 427

Countries citing papers authored by André Jefremow

Since Specialization
Citations

This map shows the geographic impact of André Jefremow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André Jefremow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André Jefremow more than expected).

Fields of papers citing papers by André Jefremow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by André Jefremow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André Jefremow. The network helps show where André Jefremow may publish in the future.

Co-authorship network of co-authors of André Jefremow

This figure shows the co-authorship network connecting the top 25 collaborators of André Jefremow. A scholar is included among the top collaborators of André Jefremow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with André Jefremow. André Jefremow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Jefremow, André & Markus F. Neurath. (2023). Novel Small Molecules in IBD: Current State and Future Perspectives. Cells. 12(13). 1730–1730. 24 indexed citations
2.
Thoma, Oana‐Maria, Elisabeth Naschberger, Markéta Kubánková, et al.. (2023). p21 Prevents the Exhaustion of CD4+ T Cells Within the Antitumor Immune Response Against Colorectal Cancer. Gastroenterology. 166(2). 284–297.e11. 11 indexed citations
3.
Jefremow, André & Markus F. Neurath. (2021). New agents for immunosuppression. Best Practice & Research Clinical Gastroenterology. 54-55. 101763–101763. 4 indexed citations
4.
Jefremow, André, Markus F. Neurath, & Maximilian J. Waldner. (2021). CRISPR/Cas9 in Gastrointestinal Malignancies. Frontiers in Cell and Developmental Biology. 9. 727217–727217. 5 indexed citations
5.
Jefremow, André & Markus F. Neurath. (2020). Nanoparticles in Gastrooncology. Visceral Medicine. 36(2). 88–94. 8 indexed citations
6.
Jefremow, André & Markus F. Neurath. (2020). SARS-CoV-2 Virus Manifestations in the Gastrointestinal Tract: Therapeutic Implications. Visceral Medicine. 37(1). 63–69. 3 indexed citations
7.
Jefremow, André & Markus F. Neurath. (2020). <p>All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD – A Clinical Perspective</p>. ImmunoTargets and Therapy. Volume 9. 289–297. 25 indexed citations
9.
Jefremow, André, Peter Dietrich, Andreas E. Kremer, et al.. (2020). Safety and efficacy of lenvatinib in HCC beyond second-line treatment.. Journal of Clinical Oncology. 38(15_suppl). e16592–e16592. 1 indexed citations
10.
Neufert, Clemens, Christoph Becker, Özlem Türeci, et al.. (2013). Tumor fibroblast–derived epiregulin promotes growth of colitis-associated neoplasms through ERK. Journal of Clinical Investigation. 123(4). 1428–1443. 93 indexed citations
11.
Waldner, Maximilian J., Stefan Wirtz, André Jefremow, et al.. (2010). VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. The Journal of Experimental Medicine. 207(13). 2855–2868. 142 indexed citations
12.
Wirtz, Stefan, André Jefremow, Clemens Neufert, et al.. (2010). VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. The Journal of Cell Biology. 191(5). i12–i12. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026